发明授权
- 专利标题： Substituted cycloalkyl P1′ hepatitis C virus inhibitors
- 专利标题（中）： 取代环烷基P1'丙型肝炎病毒抑制剂
-
申请号： US10441428申请日： 2003-05-20
-
公开(公告)号： US06878722B2公开(公告)日： 2005-04-12
- 发明人: Jeffrey Allen Campbell , Stanley D'Andrea , Andrew Good , Jianqing Li , Fiona Mcphee , Amy Ripka , Paul Michael Scola , Yong Tu
- 申请人： Jeffrey Allen Campbell , Stanley D'Andrea , Andrew Good , Jianqing Li , Fiona Mcphee , Amy Ripka , Paul Michael Scola , Yong Tu
- 申请人地址： US NJ Princeton
- 专利权人： Bristol-Myers Squibb Company
- 当前专利权人： Bristol-Myers Squibb Company
- 当前专利权人地址： US NJ Princeton
- 代理商 Warren K. Volles
- 主分类号： A61K
- IPC分类号： A61K20060101 ; A61K31/47 ; A61K31/4709 ; A61K38/05 ; A61K38/21 ; A61P31/12 ; C07D401/02 ; C07D401/12 ; C07K5/06 ; C07K5/08 ; C07K5/083 ; C07K5/087
摘要：
The present invention relates to tripeptide compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. In particular, the present invention provides novel tripeptide analogs, pharmaceutical compositions containing such analogs and methods for using these analogs in the treatment of HCV infection.
公开/授权文献
- US20040077551A1 Substituted cycloalkyl P1' hepatitis C virus inhibitors 公开/授权日：2004-04-22
信息查询
